Pronota Receives $2M to Further Development of Cardiovascular Biomarkers

The company is developing biomarkers with the goal of addressing shortcomings in two existing biomarkers for heart failure: BNP and NT-proBNP.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.